Buchumschlag

Introducing MCC-PS: a novel prognostic score for Merkel cell carcinoma

Introduction - Merkel cell carcinoma (MCC) is an aggressive skin cancer with a poor prognosis, which only improved with the introduction of immunotherapies. An MCC prediction model with high diagnostic accuracy is lacking. The aim was to develop an MCC prognostic score (MCC-PS) based on combinations...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Abu Rached, Nessr (VerfasserIn) , Becker, Jürgen C. (VerfasserIn) , Lonsdorf, Anke Susanne (VerfasserIn) , Keller, Aric (VerfasserIn) , Zeglis, Ioannis A. (VerfasserIn) , Gambichler, Thilo (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 22 July 2024
In: Frontiers in oncology
Year: 2024, Jahrgang: 14, Pages: 1-8
ISSN:2234-943X
DOI:10.3389/fonc.2024.1427740
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fonc.2024.1427740
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1427740/full
Volltext
Verfasserangaben:Nessr Abu Rached, Jürgen C. Becker, Anke S. Lonsdorf, Aric Keller, Ioannis A. Zeglis and Thilo Gambichler

MARC

LEADER 00000naa a2200000 c 4500
001 1931361614
003 DE-627
005 20250721104551.0
007 cr uuu---uuuuu
008 250721s2024 xx |||||o 00| ||eng c
024 7 |a 10.3389/fonc.2024.1427740  |2 doi 
035 |a (DE-627)1931361614 
035 |a (DE-599)KXP1931361614 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Abu Rached, Nessr  |d 1995-  |e VerfasserIn  |0 (DE-588)1253905479  |0 (DE-627)1796292540  |4 aut 
245 1 0 |a Introducing MCC-PS  |b a novel prognostic score for Merkel cell carcinoma  |c Nessr Abu Rached, Jürgen C. Becker, Anke S. Lonsdorf, Aric Keller, Ioannis A. Zeglis and Thilo Gambichler 
264 1 |c 22 July 2024 
300 |b Illustrationen 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 21.07.2025 
520 |a Introduction - Merkel cell carcinoma (MCC) is an aggressive skin cancer with a poor prognosis, which only improved with the introduction of immunotherapies. An MCC prediction model with high diagnostic accuracy is lacking. The aim was to develop an MCC prognostic score (MCC-PS) based on combinations of previously proposed risk factors. - - Methods - A multicentric, retrospective study was conducted to develop MCC-PS, which included age, neuron-specific enolase (NSE), C-reactive protein (CRP), creatinine, bilirubin, and international normalized ratio (INR). Creatinine, bilirubin, and INR were used to calculate the model of end-stage liver disease (MELD) score. A total of 98 patients were included in the study, including 36.7% with stage I according to American Joint Committee on Cancer 2018 (n = 36), 30.6% with stage II (n = 30), 25.5% with stage III (n = 25), and 7.1% with stage IV (n = 7). Survival data of MCC patients were correlated with selected laboratory parameters and risk factors. Primary endpoint was MCC-specific survival (MSS) and the secondary endpoint was progression-free survival. Several statistical methods were used to develop the prognostic score, including correlation analysis, Kaplan-Meier curves, Cox regression, and time-dependent receiver operating characteristic analysis. - - Results - The MCC-PS is based on the sum of the following baseline variables: elevated CRP (≥5.5 mg/l), elevated NSE (≥22.8 µg/l), MELD score ≥ 11, and age ≥ 75 years. An MELD score ≥ 11 was scored as 4 points, elevated NSE level as 3 points, elevated CRP level as 2 points, and age ≥ 75 years as 1 point. A high-risk group according to the MCC-PS was characterized by a score of 4 or more points. The high-risk group was associated with a worse prognosis than the low-risk group (1-year MSS 62%, 2-year 43.1%, 5-year 17.6% as compared to 1-year MSS 79.5%, 3-year 75%, 5-year 72%). Notably, the developed MCC-PS predicts MCC outcome measures with high accuracy (3-year MSS: area under the curve (AUC) 0.934, sensitivity 87.5% and specificity 82.2%; 5-year MSS: AUC 0.93, sensitivity 89% and specificity 82%). - - Conclusion - MCC-PS is the first prognostic score predicting MCC outcome with a high accuracy based on five easily available laboratory parameters and patient’s age. An MCC-PS of 4 or more indicates a high-risk patient associated with a poor prognosis. 
650 4 |a biomarkers 
650 4 |a death 
650 4 |a MCC-PS 
650 4 |a merkel cell carcinoma 
650 4 |a Merkel cell carcinoma prognosis score 
650 4 |a Prognostic score 
650 4 |a relapse 
700 1 |a Becker, Jürgen C.  |d 1964-  |e VerfasserIn  |0 (DE-588)129853437  |0 (DE-627)481957863  |0 (DE-576)216700434  |4 aut 
700 1 |a Lonsdorf, Anke Susanne  |d 1977-  |e VerfasserIn  |0 (DE-588)130004944  |0 (DE-627)486918939  |0 (DE-576)297945904  |4 aut 
700 1 |a Keller, Aric  |d 1990-  |e VerfasserIn  |0 (DE-588)1263697879  |0 (DE-627)1811812244  |4 aut 
700 1 |a Zeglis, Ioannis A.  |e VerfasserIn  |4 aut 
700 1 |a Gambichler, Thilo  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in oncology  |d Lausanne : Frontiers Media, 2011  |g 14(2024), Artikel-ID 1427740, Seite 1-8  |h Online-Ressource  |w (DE-627)684965518  |w (DE-600)2649216-7  |w (DE-576)35841184X  |x 2234-943X  |7 nnas  |a Introducing MCC-PS a novel prognostic score for Merkel cell carcinoma 
773 1 8 |g volume:14  |g year:2024  |g elocationid:1427740  |g pages:1-8  |g extent:8  |a Introducing MCC-PS a novel prognostic score for Merkel cell carcinoma 
856 4 0 |u https://doi.org/10.3389/fonc.2024.1427740  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1427740/full  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250721 
993 |a Article 
994 |a 2024 
998 |g 1263697879  |a Keller, Aric  |m 1263697879:Keller, Aric  |d 910000  |d 911300  |e 910000PK1263697879  |e 911300PK1263697879  |k 0/910000/  |k 1/910000/911300/  |p 4 
998 |g 130004944  |a Lonsdorf, Anke Susanne  |m 130004944:Lonsdorf, Anke Susanne  |d 910000  |d 911300  |e 910000PL130004944  |e 911300PL130004944  |k 0/910000/  |k 1/910000/911300/  |p 3 
999 |a KXP-PPN1931361614  |e 4748246456 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"title":[{"title_sort":"Frontiers in oncology","title":"Frontiers in oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2024","extent":"8","volume":"14","pages":"1-8","text":"14(2024), Artikel-ID 1427740, Seite 1-8"},"origin":[{"publisher":"Frontiers Media","dateIssuedKey":"2011","publisherPlace":"Lausanne","dateIssuedDisp":"2011-"}],"id":{"eki":["684965518"],"zdb":["2649216-7"],"issn":["2234-943X"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"pubHistory":["2011 -"],"note":["Gesehen am 07.11.13"],"recId":"684965518","disp":"Introducing MCC-PS a novel prognostic score for Merkel cell carcinomaFrontiers in oncology"}],"title":[{"title_sort":"Introducing MCC-PS","subtitle":"a novel prognostic score for Merkel cell carcinoma","title":"Introducing MCC-PS"}],"person":[{"role":"aut","given":"Nessr","family":"Abu Rached","display":"Abu Rached, Nessr"},{"display":"Becker, Jürgen C.","family":"Becker","given":"Jürgen C.","role":"aut"},{"given":"Anke Susanne","display":"Lonsdorf, Anke Susanne","family":"Lonsdorf","role":"aut"},{"role":"aut","given":"Aric","display":"Keller, Aric","family":"Keller"},{"role":"aut","given":"Ioannis A.","family":"Zeglis","display":"Zeglis, Ioannis A."},{"given":"Thilo","family":"Gambichler","display":"Gambichler, Thilo","role":"aut"}],"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"22 July 2024"}],"language":["eng"],"id":{"doi":["10.3389/fonc.2024.1427740"],"eki":["1931361614"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1931361614","note":["Gesehen am 21.07.2025"],"name":{"displayForm":["Nessr Abu Rached, Jürgen C. Becker, Anke S. Lonsdorf, Aric Keller, Ioannis A. Zeglis and Thilo Gambichler"]}} 
SRT |a ABURACHEDNINTRODUCIN2220 

Ähnliche Einträge